Immunoglobulin recombinase gene activity is modulated reciprocally by interleukin 7 and CD19 in B cell progenitors
- PMID: 7561700
- PMCID: PMC2192306
- DOI: 10.1084/jem.182.4.973
Immunoglobulin recombinase gene activity is modulated reciprocally by interleukin 7 and CD19 in B cell progenitors
Abstract
Bone marrow stromal cells promote B cell development involving recombinase gene-directed rearrangement of the immunoglobulin genes. We observed that the stromal cell-derived cytokine interleukin 7 (IL-7) enhances the expression of CD19 molecules on progenitor B-lineage cells in human bone marrow samples and downregulates the expression of terminal deoxynucleotidyl transferase (TdT) and the recombinase-activating genes RAG-1 and RAG-2. Initiation of the TdT downregulation on the first day of treatment, CD19 upregulation during the second day, and RAG-1 and RAG-2 downmodulation during the third day implied a cascade of IL-7 effects. While CD19 ligation by divalent antibodies had no direct effect on TdT or RAG gene expression, CD19 cross-linkage complete blocked the IL-7 downregulation of RAG expression without affecting the earlier TdT response. These results suggest that signals generated through CD19 and the IL-7 receptor could modulate immunoglobulin gene rearrangement and repertoire diversification during the early stages of B cell differentiation.
Similar articles
-
Ordering of human bone marrow B lymphocyte precursors by single-cell polymerase chain reaction analyses of the rearrangement status of the immunoglobulin H and L chain gene loci.J Exp Med. 1996 Dec 1;184(6):2217-29. doi: 10.1084/jem.184.6.2217. J Exp Med. 1996. PMID: 8976177 Free PMC article.
-
Expression of interleukin-7 receptor by lineage-negative human bone marrow progenitors with enhanced lymphoid proliferative potential and B-lineage differentiation capacity.Blood. 1997 Feb 1;89(3):929-40. Blood. 1997. PMID: 9028324
-
Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny.Blood. 1998 Nov 1;92(9):3203-9. Blood. 1998. PMID: 9787156
-
Function and control of recombination-activating gene activity.Ann N Y Acad Sci. 1992 May 4;651:277-94. doi: 10.1111/j.1749-6632.1992.tb24626.x. Ann N Y Acad Sci. 1992. PMID: 1599127 Review.
-
Fidelity and infidelity in commitment to B-lymphocyte lineage development.Immunol Rev. 2000 Jun;175:104-11. Immunol Rev. 2000. PMID: 10933595 Review.
Cited by
-
Agammaglobulinemia associated with BCR⁻ B cells and enhanced expression of CD19.Blood. 2011 Aug 18;118(7):1828-37. doi: 10.1182/blood-2011-01-330472. Epub 2011 Jun 21. Blood. 2011. PMID: 21693761 Free PMC article.
-
Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.Am J Clin Exp Immunol. 2017 May 15;6(3):27-42. eCollection 2017. Am J Clin Exp Immunol. 2017. PMID: 28804691 Free PMC article. Review.
-
ATM-dependent Phosphorylation of Nemo SQ Motifs Is Dispensable for Nemo-mediated Gene Expression Changes in Response to DNA Double-Strand Breaks.J Immunol. 2024 Sep 1;213(5):628-640. doi: 10.4049/jimmunol.2300139. J Immunol. 2024. PMID: 39007641
-
B cell receptor revision diminishes the autoreactive B cell response after antigen activation in mice.J Clin Invest. 2008 Aug;118(8):2896-907. doi: 10.1172/JCI35618. J Clin Invest. 2008. PMID: 18636122 Free PMC article.
-
Interleukin 7 independent development of human B cells.Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10348-53. doi: 10.1073/pnas.93.19.10348. Proc Natl Acad Sci U S A. 1996. PMID: 8816803 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical